Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
145.4 USD | +1.48% | +4.75% | +41.81% |
28/06 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
28/06 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Evolution of the average Target Price on Novo Nordisk A/S
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Novo Nordisk A/S
UBS | Jo Walton |
JPMORGAN | Richard Vosser |
GOLDMAN SACHS | James Quigley |
DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
JEFFERIES | Peter Welford |
Argus | |
Stifel Nicolaus | |
BERENBERG | Kerry Holford |
DZ BANK | Elmar Kraus |
BARCLAYS | Emily Field |
alphavalue | Abhishek Raval |
BERNSTEIN RESEARCH | Florent Cespedes |
BMO Capital | |
Cantor Fitzgerald | |
TD Cowen | |
ODDO BHF | |
Berenberg Bank | |
CREDIT SUISSE | Lorenzo Biasio |
Morgan Stanley | |
BNP Paribas Exane | |
JPMorgan Chase | |
Guggenheim | |
Bryan, Garnier & Co. | |
Deutsche Bank Securities | |
DEUTSCHE BANK | Emmanuel Papadakis |
Liberum Capital | |
KEPLER CHEUVREUX | David Evans |
HSBC | Stephen McGarry |
INDEPENDENT RESEARCH | Tobias Gottschalt |
BANK OF AMERICA (BOFA) | Sachin Jain |
EPS Revisions
- Stock Market
- Equities
- NOVO B Stock
- NONOF Stock
- Consensus Novo Nordisk A/S